Skip to main content
PMC home page
Springer logoLink to Springer
. 2017 Oct 25;167(1):407. doi: 10.1007/s10549-017-4539-3

Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients

Carlo Palmieri 1,2,3,✉, Rob C Stein 4, Xinxue Liu 3, Emma Hudson 3, Hanna Nicholas 3, Hironobu Sasano 5, Fouzia Guestini 5, Chris Holcombe 6, Sophie Barrett 7, Laura Kenny 3, Sadie Reed 3, Adrian Lim 8, Larry Hayward 9, Sacha Howell 10, R Charles Coombes 3; On behalf of the IRIStrial participants
PMCID: PMC6828374  PMID: 29071491

Correction to: Breast Cancer Res Treat DOI 10.1007/s10549-017-4328-z

In the original publication of the article, a part of acknowledgement section was missed out. The omitted acknowledgement is given below:

‘The study was coordinated by the Imperial Clinical Trials Unit—Cancer, Imperial College London and Sponsored by Imperial College London. The Imperial Clinical Trials Unit receives funding from the National Institute for Health (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This study was supported by Imperial Experimental Cancer Medicine Centre and Cancer Research UK Imperial Centre’.

Footnotes

The online version of the original article can be found under doi:10.1007/s10549-017-4328-z.

Articles from Breast Cancer Research and Treatment are provided here courtesy of Springer

RESOURCES